Table 6.
Expected results under different scenarios analyses
| Scenario | Total
|
Incremental
|
|||
|---|---|---|---|---|---|
| Costs | QALYs | Costs | QALYs | ICUR | |
| 1. Inclusion of add-back therapy | |||||
| Scenario a: 100% on add-back, no hot flashes in the leuprolide arm | |||||
| Leuprolide | $1,366.36 | 0.171 | -reference- | -reference- | |
| Ulipristal | $1,273.47 | 0.177 | $-92.89 | 0.006 | Ulipristal dominates leuprolide |
| Scenario b: 39% on add-back, no hot flashes in the leuprolide arm | |||||
| Leuprolide | $1,365.00 | 0.171 | -reference- | -reference- | |
| Ulipristal | $1,273.66 | 0.177 | $-91.34 | 0.006 | Ulipristal dominates leuprolide |
| Scenario c: 39% on add-back, 50% reduction in hot flashes in the leuprolide arm | |||||
| Leuprolide | $1,366.24 | 0.168 | -reference- | -reference- | |
| Ulipristal | $1,273.11 | 0.177 | $-93.14 | 0.009 | Ulipristal dominates leuprolide |
| 2. 11.25 mg leuprolide | |||||
| Leuprolide | $1,271.14 | 0.165 | -reference- | -reference- | |
| Ulipristal | $1,273.08 | 0.177 | 1.93 | 0.012 | 168.39 |
| 3. Societal perspective | |||||
| Leuprolide | $1,614.50 | 0.165 | -reference- | -reference- | |
| Ulipristal | $1,416.77 | 0.177 | $-197.74 | 0.012 | Ulipristal dominates leuprolide |
Note: Costs in 2013 Canadian dollars.
Abbreviations: QALYs, quality-adjusted life years; ICUR, incremental cost-utility ratio.